SpringWorks Book Value Per Share from 2010 to 2024

SWTX Stock

USD 41.22 1.83 4.65%

SpringWorks Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 5.54 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of SpringWorks Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

9.9204682

Current Value

5.54

Quarterly Volatility

4.96593439

Credit Downgrade

Yuan Drop

Covid

Check SpringWorks Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SpringWorks Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 923.7 K, Selling General Administrative of 207.4 M or Total Revenue of 5.2 M, as well as many indicators such as Price To Sales Ratio of 444, Dividend Yield of 0.0 or PTB Ratio of 3.86. SpringWorks financial statements analysis is a perfect complement when working with SpringWorks Therapeutics Valuation or Volatility modules.

Check out the analysis of SpringWorks Therapeutics Correlation against competitors.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

Latest SpringWorks Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of SpringWorks Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. SpringWorks Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SpringWorks Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 7.17 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

SpringWorks Book Value Per Share Regression Statistics

	Arithmetic Mean	3.58
	Coefficient Of Variation	138.87
	Mean Deviation	4.47
	Median	(0.06)
	Standard Deviation	4.97
	Sample Variance	24.66
	Range	13.7377
	R-Value	0.77
	Mean Square Error	10.74
	R-Squared	0.60
	Significance	0.0008
	Slope	0.86
	Total Sum of Squares	345.25

SpringWorks Book Value Per Share History

	2024	5.54
	2023	9.92
	2022	10.47
	2021	8.71
	2020	12.87
	2019	7.49
	2018	-0.87

Other Fundumenentals of SpringWorks Therapeutics

Tangible Book Value Per Share

SpringWorks Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Intangible Assets	Common Stock	Property Plant Equipment	Long Term Debt	Good Will	Net Tangible Assets	Net Debt	Retained Earnings	Net Invested Capital	Total Current Assets	Net Working Capital	Capital Surpluse	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt
Total Assets		0.53	0.43	0.12	0.69	0.64	0.31	0.65	0.28	-0.19	-0.64	0.94	-0.68	-0.89	0.96	0.95	0.94	0.96	0.93	-0.94	0.93	0.83
Total Stockholder Equity	0.53		0.09	-0.31	0.28	0.6	0.25	0.45	0.0	-0.13	-0.6	0.45	-0.63	-0.43	0.47	0.38	0.37	0.57	0.54	-0.53	0.47	0.71
Accounts Payable	0.43	0.09		-0.64	0.67	0.34	-0.65	0.68	0.98	0.76	-0.34	0.32	-0.17	-0.46	0.33	0.33	0.32	0.33	0.32	-0.31	0.35	0.21
Short Term Investments	0.12	-0.31	-0.64		-0.17	-0.1	0.79	-0.33	-0.7	-0.85	0.08	0.19	-0.06	-0.11	0.19	0.25	0.26	0.15	0.14	-0.17	0.12	-0.03
Total Liab	0.69	0.28	0.67	-0.17		0.73	0.01	0.79	0.58	0.15	-0.74	0.5	-0.3	-0.84	0.52	0.52	0.49	0.54	0.51	-0.48	0.61	0.42
Treasury Stock	0.64	0.6	0.34	-0.1	0.73		0.31	0.59	0.25	-0.15	-0.8	0.53	-0.4	-0.84	0.54	0.45	0.41	0.54	0.59	-0.46	0.6	0.5
Intangible Assets	0.31	0.25	-0.65	0.79	0.01	0.31		-0.07	-0.76	-0.98	-0.34	0.3	-0.28	-0.36	0.31	0.31	0.3	0.34	0.32	-0.32	0.31	0.28
Common Stock	0.65	0.45	0.68	-0.33	0.79	0.59	-0.07		0.6	0.25	-0.88	0.37	-0.32	-0.74	0.41	0.41	0.39	0.53	0.38	-0.46	0.49	0.44
Property Plant Equipment	0.28	0.0	0.98	-0.7	0.58	0.25	-0.76	0.6		0.85	-0.23	0.19	-0.01	-0.32	0.19	0.19	0.18	0.17	0.17	-0.15	0.23	0.11
Long Term Debt	-0.19	-0.13	0.76	-0.85	0.15	-0.15	-0.98	0.25	0.85		0.15	-0.23	0.21	0.21	-0.23	-0.24	-0.23	-0.25	-0.24	0.24	-0.21	-0.2
Good Will	-0.64	-0.6	-0.34	0.08	-0.74	-0.8	-0.34	-0.88	-0.23	0.15		-0.38	0.41	0.81	-0.42	-0.38	-0.36	-0.54	-0.43	0.45	-0.49	-0.46
Net Tangible Assets	0.94	0.45	0.32	0.19	0.5	0.53	0.3	0.37	0.19	-0.23	-0.38		-0.67	-0.76	1.0	0.99	0.98	0.94	0.98	-0.95	0.93	0.83
Net Debt	-0.68	-0.63	-0.17	-0.06	-0.3	-0.4	-0.28	-0.32	-0.01	0.21	0.41	-0.67		0.48	-0.68	-0.67	-0.68	-0.81	-0.78	0.81	-0.44	-0.47
Retained Earnings	-0.89	-0.43	-0.46	-0.11	-0.84	-0.84	-0.36	-0.74	-0.32	0.21	0.81	-0.76	0.48		-0.78	-0.75	-0.72	-0.79	-0.77	0.73	-0.83	-0.64
Net Invested Capital	0.96	0.47	0.33	0.19	0.52	0.54	0.31	0.41	0.19	-0.23	-0.42	1.0	-0.68	-0.78		0.99	0.98	0.96	0.98	-0.96	0.94	0.84
Total Current Assets	0.95	0.38	0.33	0.25	0.52	0.45	0.31	0.41	0.19	-0.24	-0.38	0.99	-0.67	-0.75	0.99		1.0	0.95	0.95	-0.96	0.91	0.79
Net Working Capital	0.94	0.37	0.32	0.26	0.49	0.41	0.3	0.39	0.18	-0.23	-0.36	0.98	-0.68	-0.72	0.98	1.0		0.95	0.94	-0.96	0.9	0.79
Capital Surpluse	0.96	0.57	0.33	0.15	0.54	0.54	0.34	0.53	0.17	-0.25	-0.54	0.94	-0.81	-0.79	0.96	0.95	0.95		0.96	-0.99	0.87	0.8
Deferred Long Term Liab	0.93	0.54	0.32	0.14	0.51	0.59	0.32	0.38	0.17	-0.24	-0.43	0.98	-0.78	-0.77	0.98	0.95	0.94	0.96		-0.96	0.88	0.79
Capital Stock	-0.94	-0.53	-0.31	-0.17	-0.48	-0.46	-0.32	-0.46	-0.15	0.24	0.45	-0.95	0.81	0.73	-0.96	-0.96	-0.96	-0.99	-0.96		-0.85	-0.79
Current Deferred Revenue	0.93	0.47	0.35	0.12	0.61	0.6	0.31	0.49	0.23	-0.21	-0.49	0.93	-0.44	-0.83	0.94	0.91	0.9	0.87	0.88	-0.85		0.91
Short Term Debt	0.83	0.71	0.21	-0.03	0.42	0.5	0.28	0.44	0.11	-0.2	-0.46	0.83	-0.47	-0.64	0.84	0.79	0.79	0.8	0.79	-0.79	0.91

Click cells to compare fundamentals

About SpringWorks Therapeutics Financial Statements

SpringWorks Therapeutics investors use historical fundamental indicators, such as SpringWorks Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SpringWorks Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	9.92	5.54
Tangible Book Value Per Share	9.74	5.53

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC